Clinical trials: High Risk Smoldering Multiple Myeloma
Smoldering Multiple Myeloma
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
This study will assess the antimyeloma effects of BHQ880A in patients with smoldering multiple myeloma with high risk of progression to active multiple myeloma.
- Trial name
- NCT01302886
- Testing
- BHQ880
- Where
- 13 sites in United States, France and 1 more
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Smoldering Multiple Myeloma
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
This is a multicenter, single arm, open-label, Phase 2 study in high risk smoldering myeloma patients. The primary objective is to determine the efficacy of Elranatamab in patients with previously untreated high-risk SMM.
- Trial name
- ERASMM (NCT06183489)
- Testing
- Elranatamab
- Where
- 18 sites in France, Italy and 2 more
- Volunteers
- 50 people
- Sponsor
- European Myeloma Network B.V.
Smoldering Multiple Myeloma
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
The purpose of this study is to determine whether elotuzumab will improve response in patients with high risk smoldering myeloma who have more CD56^dim cells (a marker for the health of the body's immune system)
- Trial name
- NCT01441973
- Testing
- Elotuzumab (BMS-901608; HuLuc63)
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
This is a randomized, 2-arm phase II, placebo-controlled, multi-center study, where the investigators aim to evaluate whether the reported benefits of denosumab, delay of SRE and decrease in myeloma growth promotion, reduce the…
- Trial name
- DEFENCE (NCT03792763)
- Testing
- Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
- Where
- 10 sites in Austria, Germany and 1 more
- Volunteers
- 8 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Smoldering Plasma Cell Myeloma
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma.
- Trial name
- NCT03937635
- Testing
- Daratumumab, Dexamethasone, Lenalidomide
- Where
- 748 sites in United States, Puerto Rico
- Volunteers
- 288 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Multiple Myeloma, Smoldering Multiple Myeloma
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe and effective in treating participants with high-risk, smoldering myeloma.
- Trial name
- NCT05767359
- Testing
- Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Smoldering Multiple Myeloma
PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma
This study is evaluating a new vaccine against PD-L1 as a possible treatment for high-risk smoldering multiple myeloma.
- Trial name
- NCT03850522
- Testing
- PD-L1 peptide
- Where
- Denmark
- Volunteers
- 6 people
- Sponsor
- Lene Meldgaard Knudsen
Smouldering Myeloma
Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM
Randomized (2:1) multi-center open-label phase II trial. Patients with high-risk SMM will be enrolled on the study and treated with KRd combination (Cycles 1-9 carfilzomib 20/36 mg/m2, lenalidomide 25 mg, dexamethasone 20 mg…
- Trial name
- HO147SMM (NCT03673826)
- Testing
- Carfilzomib, Dexamethasone, Lenalidomide
- Where
- 16 sites in Czechia, Italy and 2 more
- Volunteers
- 58 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
High-risk Smoldering Multiple Myeloma
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of siltuximab compared with placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial) in patients…
- Trial name
- NCT01484275
- Testing
- Siltuximab
- Where
- 40 sites in United States, Australia and 9 more
- Volunteers
- 85 people
- Sponsor
- Janssen Research & Development, LLC
Smoldering Plasma Cell Myeloma
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
This pilot early phase I trial studies pembrolizumab in treating patients with slow growing (smoldering) multiple myeloma with intermediate or high-risk of spreading.
- Trial name
- NCT02603887
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma, High Risk Smoldering Multiple Myeloma
Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study
The purpose of this study is to see what effects, good and/or bad, the combination of ixazomib and dexamethasone has on the patient and the smoldering multiple myeloma.
- Trial name
- NCT02697383
- Testing
- Ixazomib (MLN9708), Dexamethasone
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Smoldering Multiple Myeloma
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM).
- Trial name
- ASCENT (NCT03289299)
- Testing
- Carfilzomib, Lenalidomide, Daratumumab
- Where
- 10 sites in United States
- Volunteers
- 87 people
- Sponsor
- International Myeloma Foundation
Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
This study is researching an investigational drug called linvoseltamab ("study drug") in participants at moderate risk of developing multiple myeloma (about 3 to 10% average annual risk), a group that consists of patients with…
- Trial name
- LINKER-MGUS1 (NCT06140524)
- Testing
- Linvoseltamab
- Where
- 39 sites in United States, Belgium and 5 more
- Volunteers
- 116 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
The purpose of this study is to see whether combination treatment of Teclistamab and Daratumumab (Tel-Dara) or combination Talquetamab and Daratumumab (Tal-Dara) will delay the onset of multiple myeloma.
- Trial name
- REVIVE (NCT06100237)
- Testing
- Teclistamab, Talquetamab, Daratumumab SC
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Carl Ola Landgren, MD, PhD
Smoldering Multiple Myeloma
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood stem cell transplantation.
- Trial name
- NCT02415413
- Testing
- carfilzomib, Lenalidomide, Dexamethasone
- Where
- 16 sites in Spain
- Volunteers
- 90 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma, Smoldering Multiple Myeloma
The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma
The goal of this clinical trial is to test the safety, tolerability, and efficacy of TG01 vaccination in patients with KRAS or NRAS mutation on codon 12/13 mutation who has multiple myeloma or high-risk smoldering multiple…
- Trial name
- NCT05841550
- Testing
- TG01
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Oslo University Hospital
Multiple Myeloma
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma
Background: Smoldering multiple myeloma (SMM) is a condition that can lead to multiple myeloma, a type of blood cancer. In many high-risk cases, SMM can develop into multiple myeloma in less than 2 years.
- Trial name
- NCT01660997
- Testing
- MLN9708, Dexamethasone
- Sponsor
- National Cancer Institute (NCI)
Smoldering Plasma Cell Myeloma
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma.
- Trial name
- NCT05014646
- Testing
- Cholestyramine, Leflunomide
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- City of Hope Medical Center
Smouldering Myeloma
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
The study will test a new combination of 3 drugs: Isatuximab (Isa), Iberdomide (Iber) and Dexamethasone (Dex), in patients who have intermediate or high risk smouldering myeloma.
- Trial name
- MODIFY (NCT06762769)
- Testing
- Isatuximab, Iberdomide, Dexamethasone
- Where
- 14 sites in United Kingdom
- Volunteers
- 63 people
- Sponsor
- University College, London
High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma.
- Conditions
- High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma
- Trial name
- NCT05469893
- Testing
- Teclistamab, Lenalidomide, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- Irene Ghobrial, MD